← Back to Search

18F-FluorThanatrace PET/CT Imaging for Prostate Cancer

Q: Are new participants still being accepted for this clinical research?

At present, this clinical trial is not accepting any further patients. It was initially published on July 14th 2017 and last modified on May 12th 2022. There are 1322 studies open for enrolment that involve <a href="https://www.withpower.com/clinical-trials/prostate-cancer">prostate cancer</a>, as well as two trials concerning Poly(ADP Ribose)Polymerase 1 with vacancies still available.

Q: What is the upper limit of patients who have consented to participate in this clinical trial?

This scientific study is no longer actively recruiting. It was initially advertised on July 14th 2017 and the latest revision took place on May 12th 2022. If you are looking for alternative trials, there are 1322 <a href="https://www.withpower.com/clinical-trials/prostate-cancer">prostate cancer</a> studies now inviting volunteers as well 2 Poly(ADP Ribose) Polymerase 1 investigations that need participants to join.

Q: Could you elaborate on the research that has been conducted regarding Poly(ADP Ribose) Polymerase 1?

Currently, there are 2 active studies for Poly(ADP Ribose) Polymerase 1 in its pre-Phase 3 stages. These experiments have been established in two different locations - one of them being San Francisco, <a href="https://www.withpower.com/clinical-trials/california">California</a>.

Phase < 1

Waitlist Available

Led By Dan Pryma, MD

Research Sponsored by Abramson Cancer Center of the University of Pennsylvania

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Participants must be ≥ 18 years of age

Participants must have biopsy-proven prostate cancer

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 years

Awards & highlights

Study Summary

This trial is testing a new imaging technique to see if it can accurately find where prostate cancer is in the body.

Who is the study for?

Men over 18 with biopsy-proven prostate cancer, who have at least one tumor lesion of 1 cm or larger. They must be recommended for a prostatectomy or oligometastectomy and willing to provide tissue samples for research. Excluded are those unable to tolerate imaging, with serious health/psychological issues, or unable to give informed consent.Check my eligibility

What is being tested?

The study tests a new PET/CT imaging method using [18F]FluorThanatrace (FTT) to measure PARP-1 activity in primary or metastatic prostate cancer sites. The results will be compared with pathology findings from surgeries like prostatectomies.See study design

What are the potential side effects?

[18F]FluorThanatrace is used for imaging and may cause discomfort at the injection site, allergic reactions, and exposure to radiation typical of PET/CT scans which carries a small risk of future cancer.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

My prostate cancer diagnosis was confirmed through a biopsy.

Select...

I am recommended to undergo surgery for prostate cancer.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of adverse events

Trial Design

3Treatment groups

Experimental Treatment

Group I: Cohort 3Experimental Treatment2 Interventions

Gleason 9 or oligometastic disease (n=10)

Group II: Cohort 2Experimental Treatment2 Interventions

Gleason 7-8 (n=10)

Group III: Cohort 1Experimental Treatment2 Interventions

Gleason 6 (n=10)

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Abramson Cancer Center of the University of PennsylvaniaLead Sponsor

359 Previous Clinical Trials

105,065 Total Patients Enrolled

12 Trials studying Prostate Cancer

1,287 Patients Enrolled for Prostate Cancer

Abramson Cancer Center at Penn MedicineLead Sponsor

387 Previous Clinical Trials

145,665 Total Patients Enrolled

12 Trials studying Prostate Cancer

1,287 Patients Enrolled for Prostate Cancer

Dan Pryma, MDPrincipal InvestigatorAbramson Cancer Center at Penn Medicine

1 Previous Clinical Trials

6 Total Patients Enrolled

Media Library

Poly(ADP Ribose) Polymerase 1 Clinical Trial Eligibility Overview. Trial Name: NCT03334500 — Phase < 1

Prostate Cancer Research Study Groups: Cohort 3, Cohort 1, Cohort 2

Prostate Cancer Clinical Trial 2023: Poly(ADP Ribose) Polymerase 1 Highlights & Side Effects. Trial Name: NCT03334500 — Phase < 1

Poly(ADP Ribose) Polymerase 1 2023 Treatment Timeline for Medical Study. Trial Name: NCT03334500 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are new participants still being accepted for this clinical research?

"At present, this clinical trial is not accepting any further patients. It was initially published on July 14th 2017 and last modified on May 12th 2022. There are 1322 studies open for enrolment that involve prostate cancer, as well as two trials concerning Poly(ADP Ribose)Polymerase 1 with vacancies still available."

Answered by AI

What is the upper limit of patients who have consented to participate in this clinical trial?

"This scientific study is no longer actively recruiting. It was initially advertised on July 14th 2017 and the latest revision took place on May 12th 2022. If you are looking for alternative trials, there are 1322 prostate cancer studies now inviting volunteers as well 2 Poly(ADP Ribose) Polymerase 1 investigations that need participants to join."

Answered by AI

Could you elaborate on the research that has been conducted regarding Poly(ADP Ribose) Polymerase 1?

"Currently, there are 2 active studies for Poly(ADP Ribose) Polymerase 1 in its pre-Phase 3 stages. These experiments have been established in two different locations - one of them being San Francisco, California."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Prostate Cancer

2017. "Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03334500.